Pragnan Kancharla
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Pragnan Kancharla has a total of 5 co-authors. Here are the top co-authors by number of shared publications:
- Ravneet K. Dhanoa
Department of Internal Medicine, MedStar Union Memorial Hospital, Baltimore, MD 21218, USA
2 shared publications - Adrien Janvier
Medicine, MedStar Franklin Square Medical Center, Baltimore, USA
1 shared publication - Madiha Kiyani
Department of Internal Medicine, MedStar Union Memorial Hospital, Baltimore, United States, USA
1 shared publication - Shweta Kurian
Department of Hematology/Oncology, MedStar Franklin Square Medical Center, Baltimore, MD 21237, USA
1 shared publication - Sumin Thapa
Postdoctoral Research Fellow, Division of Cardiovascular Medicine, University of Miami, Florida, United States
1 shared publication
Latest Publications
- Open Access
Efficacy and Toxicity of CDK4/6 Inhibitors in Early and Metastatic HR+/HER2− Breast Cancer: An Updated Meta-Analysis of Phase III Trials
Background/Objectives: CDK4/6i and ET improve outcomes in HR-positive, HER2-negative breast cancer, but their benefits differ between early-stage (EBC) and metastatic disease (MBC). We aimed to compare the efficacy and toxicity of CDK4/6i plus ET versus ET alone across these disease settings. Methods: We conducted a meta-analysis of phase III randomized trials identified through MEDLINE, EMBASE, and Web of Science up to 1 October 2025. Twenty-two trials (18 MBC, n = 6364; 4 EBC, n = 17,741) met the inclusion criteria. Two reviewers extracted data and assessed risk of bias. The study followed PRISMA 2020 guidelines (PROSPERO: CRD420251132302). Outcomes included overall survival (OS), progression-free survival (PFS), invasive disease-free survival (iDFS), distant relapse-free survival (DRFS), response rates, treatment discontinuation (TDR), dose reductions (DRR), and grade 3–4 adverse events. Results: In MBC, CDK4/6i improved OS (HR: 0.78, 95% CI: 0.72–0.85) and PFS (HR: 0.53, 95% CI: 0.50–0.56) and increased objective response, clinical benefit, and disease control rates along with TDR, DRR, and grade 3–4 adverse events. In EBC, iDFS improved, whereas OS (HR: 0.92, 95% CI: 0.75–1.12; p = 0.40) and DRFS did not. TDR, DRR, and grade 3–4 adverse events were increased. Conclusions: CDK4/6i confer significant OS and PFS benefits in MBC, supporting first-line use. In EBC, no OS benefit was observed, and toxicity was increased, underscoring the need for individualized risk–benefit assessment. Longer follow-up is warranted to clarify survival outcomes.
Open AccessEfficacy and Toxicity of CDK4/6 Inhibitors in Early and Metastatic HR+/HER2− Breast Cancer: An Updated Meta-Analysis of Phase III Trials
Background/Objectives: CDK4/6i and ET improve outcomes in HR-positive, HER2-negative breast cancer, but their benefits differ between early-stage (EBC) and metastatic disease (MBC). We aimed to compare the efficacy and toxicity of CDK4/6i plus ET versus ET alone across these disease settings. Methods: We conducted a meta-analysis of phase III randomized trials identified through MEDLINE, EMBASE, and Web of Science up to 1 October 2025. Twenty-two trials (18 MBC, n = 6364; 4 EBC, n = 17,741) met the inclusion criteria. Two reviewers extracted data and assessed risk of bias. The study followed PRISMA 2020 guidelines (PROSPERO: CRD420251132302). Outcomes included overall survival (OS), progression-free survival (PFS), invasive disease-free survival (iDFS), distant relapse-free survival (DRFS), response rates, treatment discontinuation (TDR), dose reductions (DRR), and grade 3–4 adverse events. Results: In MBC, CDK4/6i improved OS (HR: 0.78, 95% CI: 0.72–0.85) and PFS (HR: 0.53, 95% CI: 0.50–0.56) and increased objective response, clinical benefit, and disease control rates along with TDR, DRR, and grade 3–4 adverse events. In EBC, iDFS improved, whereas OS (HR: 0.92, 95% CI: 0.75–1.12; p = 0.40) and DRFS did not. TDR, DRR, and grade 3–4 adverse events were increased. Conclusions: CDK4/6i confer significant OS and PFS benefits in MBC, supporting first-line use. In EBC, no OS benefit was observed, and toxicity was increased, underscoring the need for individualized risk–benefit assessment. Longer follow-up is warranted to clarify survival outcomes.
- Open Access
- 19 May 2026
- Published by MDPI AG in Preprints.org
A Modified Simplified Frailty Score Predicts Survival, Toxicity, and Treatment Selection in Elderly Patients with Diffuse Large B-Cell Lymphoma: A Retrospective Cohort Study
Background/Objectives: Treatment decisions for elderly patients with diffuse large B-cell lymphoma (DLBCL) often rely on subjective clinical impression rather than systematic frailty assessment. We evaluated whether a modified simplified frailty score (mSFS)—a binary adaptation of the Isaksen score—predicts treatment selection, toxicity, and survival. Methods: In this retrospective study of 117 patients aged ≥65 years with DLBCL treated with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) or dose-attenuated R-CHOP (R-mini-CHOP) at MedStar Health community hospitals (2000–2025), the mSFS assigned one point each for age ≥80, Eastern Cooperative Oncology Group (ECOG) performance status ≥2, and ≥5 comorbidities; score ≥2 defined frailty. Results: Among 86 R-CHOP recipients, 17 (19.8%) were mSFS-frail; among 31 R-mini-CHOP recipients, 15 (48.4%) were mSFS-fit. In R-CHOP recipients, frailty independently predicted worse overall survival (adjusted hazard ratio [aHR] 7.67, 95% confidence interval [CI] 2.36–24.97), progression-free survival (aHR 2.90, 95% CI 1.18–7.13), grade ≥3 adverse events (adjusted odds ratio [aOR] 3.90, p = 0.035), and early discontinuation (aOR 4.41, p = 0.034). Frail R-CHOP patients had lower complete response rates (aOR 0.24, p = 0.038). Fit R-mini-CHOP patients had 88% lower odds of complete response versus fit R-CHOP patients (aOR 0.12, p = 0.003). Among R-mini-CHOP recipients, frailty was not significantly associated with outcomes. Conclusions: The mSFS revealed bidirectional discordance with oncologist-assessed frailty and independently predicted survival, toxicity, and response, supporting its integration into community oncology practice.
- 19 May 2026
- Published by MDPI AG in Preprints.org
Open AccessA Modified Simplified Frailty Score Predicts Survival, Toxicity, and Treatment Selection in Elderly Patients with Diffuse Large B-Cell Lymphoma: A Retrospective Cohort Study
Background/Objectives: Treatment decisions for elderly patients with diffuse large B-cell lymphoma (DLBCL) often rely on subjective clinical impression rather than systematic frailty assessment. We evaluated whether a modified simplified frailty score (mSFS)—a binary adaptation of the Isaksen score—predicts treatment selection, toxicity, and survival. Methods: In this retrospective study of 117 patients aged ≥65 years with DLBCL treated with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) or dose-attenuated R-CHOP (R-mini-CHOP) at MedStar Health community hospitals (2000–2025), the mSFS assigned one point each for age ≥80, Eastern Cooperative Oncology Group (ECOG) performance status ≥2, and ≥5 comorbidities; score ≥2 defined frailty. Results: Among 86 R-CHOP recipients, 17 (19.8%) were mSFS-frail; among 31 R-mini-CHOP recipients, 15 (48.4%) were mSFS-fit. In R-CHOP recipients, frailty independently predicted worse overall survival (adjusted hazard ratio [aHR] 7.67, 95% confidence interval [CI] 2.36–24.97), progression-free survival (aHR 2.90, 95% CI 1.18–7.13), grade ≥3 adverse events (adjusted odds ratio [aOR] 3.90, p = 0.035), and early discontinuation (aOR 4.41, p = 0.034). Frail R-CHOP patients had lower complete response rates (aOR 0.24, p = 0.038). Fit R-mini-CHOP patients had 88% lower odds of complete response versus fit R-CHOP patients (aOR 0.12, p = 0.003). Among R-mini-CHOP recipients, frailty was not significantly associated with outcomes. Conclusions: The mSFS revealed bidirectional discordance with oncologist-assessed frailty and independently predicted survival, toxicity, and response, supporting its integration into community oncology practice.